Salonpas is a brand name of a line of over-the-counter (OTC) pain relieving products manufactured by Hisamitsu Pharmaceutical Co., Inc. of Tosu City, Japan. Introduced to the Japanese market in 1934, Salonpas is now sold in over thirty countries. The largest markets for the products are Japan and other Asian nations such as Vietnam, Philippines, Malaysia, Taiwan. According to Hisamitsu, approximately 20 billion Salonpas transdermal patches have been sold in the last 20 years.
Similar products are marketed by other companies, including Absorbine Jr. Pain Relief, Excedrin Cooling Pads, and Icy Hot Patches.
The following is a summary of Salonpas brand products sold in the U.S.
- Salonpas Pain Relief Patch - FDA approved OTC pain relief patch. Active ingredients: Methyl Salicylate 10%, Menthol 3%
- Salonpas Arthritis Pain - FDA approved OTC pain relief patch. Active ingredients: Methyl Salicylate 10%, Menthol 3%
- Salonpas - Versatile sized OTC pain relief patch. Active ingredients: Methyl Salicylate 6.3%, Menthol 5.7%, Camphor 1.2%
- Salonpas Hot - Large size capsaicin patch for application for back—OTC pain relief patch. Active ingredient: Capsicum extract 0.025% as Capsaicin
- Air Salonpas - OTC pain relief aerosol spray. Active ingredients: Methyl Salicylate, 1.75% Menthol 3.2%, Camphor 3.0%
- Salonpas Gel - Menthol and Methyl Salicylate gel—OTC pain relief gel. Active ingredients: Methyl Salicylate 15%, Menthol 7%
- Salongsip Aqua-Patch - Menthol jelly patch—Jelly type OTC pain relief patch. Active ingredient: Menthol 1.25%
- Salonpas Gel-Patch - Menthol and capsaicin jelly patch—Active ingredients: Capsicum extracts 0.025% as Capsicum, Menthol 1.25%.
The Salonpas Pain Relief Patch and Salonpas Arthritis Pain patches are manufactured using what Hisamitsu calls “comfort stretch” technology that provides effective pain relief while allowing patients to maintain daily activities and, an alternative for those who prefer to avoid the use of oral OTC pain-relief medication for minor aches and pains. The company differentiates its products from oral medications because the active ingredients in Salonpas patches are absorbed through the skin and go directly to the site of the pain.
In February 2008, the FDA approved a New Drug Application (NDA) covering Salonpas Pain Relief Patch and Salonpas Arthritis Pain, topical pain-relieving patches. These patches contain recognized analgesic ingredients (menthol, methyl salicylate) called counterirritants, which when applied to the skin, diminish pain signals under areas to which they are administered. To date, the Salonpas Pain Relief Patch and Salonpas Arthritis Pain patch are the only external analgesic patches subject to an approved NDA and sold into the over-the-counter health care market.
The effectiveness of the Salonpas Pain Relief Patch and Salonpas Arthritis Pain patch have been established in a randomized controlled trial that was performed by Hisamitsu employees. The study, which was published in 2010, involved 208 adults with mild to moderate muscle strain. In the study, the Salonpas patch was found to provide significantly greater pain relief compared to a placebo patch, and the rates of adverse events were similar in the Salonpas and placebo groups.
- "History". Hisamitsu. Hisamitsu Pharmaceutical Co. 2015. Retrieved 2015-08-17.
- "Products". Hisamitsu. Hisamitsu Pharmaceutical Co. 2015. Retrieved 2015-08-17.
- Hisamitsu Pharmaceutical Co., Inc. Company Guide.
- Levy, Sandra (10 December 2001). "External painkillers lead sales in analgesics market". Drug Topics. Retrieved 2010-03-05.
- Pray, W. Steven (1 September 2008). "The pharmacist’s role in the appropriate selection of a nonprescription product for pain relief". U.S. Pharmacist. Retrieved 2010-03-05.
- "OTC Product News". OTC Product News. 2010-01-26. Retrieved 2013-11-28.
- Higashi Y, Kiuchi T, Furuta K (Jan 2010). "Efficacy and safety profile of a topical methyl salicylate and menthol patch in adult patients with mild to moderate muscle strain: a randomized, double-blind, parallel-group, placebo-controlled, multicenter study". Clin Ther 32 (1): 34–43. doi:10.1016/j.clinthera.2010.01.016. PMID 20171409.
- "White Paper – Clinical Trials". Salonpas. Hisamitsu America, Inc. 2010. Retrieved 2010-08-16.
- Hisamitsu Pharmaceutical Co., Inc. official website